

# Jill P Buyon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4240450/publications.pdf>

Version: 2024-02-01

210  
papers

20,735  
citations

10650

74  
h-index

12272

138  
g-index

221  
all docs

221  
docs citations

221  
times ranked

14057  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. <i>Arthritis and Rheumatology</i> , 2022, 74, 284-294.	2.9	103
2	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. <i>Rheumatology</i> , 2022, 61, 4335-4343.	0.9	6
3	Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 829-839.	2.9	38
4	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.5	9
5	High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis. <i>Journal of Rheumatology</i> , 2022, 49, 388-397.	1.0	11
6	Gut dysbiosis and the clinical spectrum in anti-Ro positive mothers of children with neonatal lupus. <i>Gut Microbes</i> , 2022, 14, .	4.3	6
7	Reducing the burden of surveillance in pregnant women with no history of fetal atrioventricular block using the negative predictive value of anti-Ro/SSA antibody titers. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 227, 761.e1-761.e10.	0.7	4
8	Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. <i>Lancet Rheumatology</i> , The, 2022, 4, e582-e585.	2.2	9
9	Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment. , 2021, , 507-519.		1
10	Passively acquired lupus in the fetus and neonate. , 2021, , 325-363.		0
11	Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021, 8, e000475.	1.1	10
12	Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	61
13	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	0.8	3
14	Microvascular endothelial glycocalyx thickness is associated with brachial artery flow-mediated dilation. <i>Vascular Medicine</i> , 2021, 26, 563-565.	0.8	2
15	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. <i>Lancet Rheumatology</i> , The, 2021, 3, e585-e594.	2.2	18
16	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. <i>Lupus Science and Medicine</i> , 2021, 8, e000522.	1.1	5
17	Autoimmune anti-DNA and anti-phosphatidylserine antibodies predict development of severe COVID-19. <i>Life Science Alliance</i> , 2021, 4, e202101180.	1.3	15
18	511...Disease flares in lupus are concordant with <i>Ruminococcus Blautia Gnavus</i> blooms arising within unstable gut microbiota communities. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	1206â€¦Evaluation of SARS-CoV-2 IgG antibody reactivity in a multi-racial/ethnic cohort of patients with systemic lupus erythematosus. , 2021, , .		2
20	901â€¦Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. , 2021, , .		0
21	1704â€¦Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
22	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	1.1	31
23	Cell atlas of the foetal human heart and implications for autoimmune-mediated congenital heart block. Cardiovascular Research, 2020, 116, 1446-1457.	1.8	80
24	Autoimmune-mediated congenital heart block. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 64, 41-51.	1.4	38
25	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care and Research, 2020, 72, 233-242.	1.5	17
26	Factors associated with long-term cardiac dysfunction in neonatal lupus. Annals of the Rheumatic Diseases, 2020, 79, 217-224.	0.5	6
27	Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal of the American College of Cardiology, 2020, 76, 292-302.	1.2	97
28	Breast feeding in the systemic lupus erythematosus patient. Lupus, 2020, 29, 1314-1315.	0.8	0
29	Leveraging the United States Epicenter to Provide Insights on COVIDâ€™19 in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 1971-1980.	2.9	51
30	Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008686.	2.1	16
31	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. Arthritis Research and Therapy, 2020, 22, 191.	1.6	21
32	Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. Nature Communications, 2020, 11, 2197.	5.8	55
33	598: The effect of maternal autoimmune disease on fetal thymus size in the mid-trimester. American Journal of Obstetrics and Gynecology, 2020, 222, S384.	0.7	0
34	Low frequency of flares during pregnancy and post-partum in stable lupus patients. Arthritis Research and Therapy, 2020, 22, 52.	1.6	37
35	Thoughts on COVID-19 and autoimmune diseases. Lupus Science and Medicine, 2020, 7, e000396.	1.1	31
36	Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science and Medicine, 2020, 7, e000377.	1.1	7

#	ARTICLE	IF	CITATIONS
37	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2020, 72, 529-556.	2.9	332
38	2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. <i>Arthritis Care and Research</i> , 2020, 72, 461-488.	1.5	122
39	Sex Differences in Systemic Lupus Erythematosus. <i>Mayo Clinic Proceedings</i> , 2020, 95, 384-394.	1.4	83
40	Gerald Weissmann: Inflammation in rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 435-436.	0.5	1
41	A review of fetal and neonatal consequences of maternal systemic lupus erythematosus. <i>Prenatal Diagnosis</i> , 2020, 40, 1066-1076.	1.1	22
42	Integrated urine proteomics and renal single-cell genomics identify an IFN- $\beta$ response gradient in lupus nephritis. <i>JCI Insight</i> , 2020, 5, .	2.3	57
43	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring <scp>SLE</scp>: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 374-382.	2.3	30
44	The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County. <i>Arthritis Care and Research</i> , 2019, 71, 949-960.	1.5	38
45	Antinuclear Antibody-“Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	1.5	70
46	Systemic Lupus Erythematosus and Increased Prevalence of Atherosclerotic Cardiovascular Disease in Hospitalized Patients. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1436-1443.	1.4	28
47	Single-cell RNA sequencing for the study of lupus nephritis. <i>Lupus Science and Medicine</i> , 2019, 6, e000329.	1.1	6
48	Population-based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program. <i>Lupus Science and Medicine</i> , 2019, 6, e000344.	1.1	22
49	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019, 20, 902-914.	7.0	501
50	Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. <i>Nature Immunology</i> , 2019, 20, 915-927.	7.0	275
51	Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. <i>Journal of Experimental Medicine</i> , 2019, 216, 1154-1169.	4.2	56
52	Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 947-956.	0.5	274
53	273-...Safety of research cores obtained from clinically indicated biopsies in the accelerating medicines partnership network. , 2019, , .		0
54	300-...Insights from single-cell RNA sequencing of skin and kidney in lupus nephritis. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	SLE: reconciling heterogeneity. <i>Lupus Science and Medicine</i> , 2019, 6, e000280.	1.1	23
56	Neonatal Lupus. , 2019, , 486-498.		1
57	Human low affinity IgG receptor FcγRIIA polymorphism H131R associates with subclinical atherosclerosis and increased platelet activity in systemic lupus erythematosus. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 532-537.	1.9	20
58	Siglec-1 Macrophages and the Contribution of IFN to the Development of Autoimmune Congenital Heart Block. <i>Journal of Immunology</i> , 2019, 202, 48-55.	0.4	39
59	PD-1hiCXCR5+ T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. <i>JCI Insight</i> , 2019, 4, .	2.3	171
60	Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 549-555.	0.5	124
61	Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 230-235.	1.5	41
62	Note of Republication: A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1074-1082.	2.3	48
63	Systemic lupus erythematosus and the risk of perioperative major adverse cardiovascular events. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 13-17.	1.0	8
64	GG-02...Apolipoprotein L1 risk variants associate with increased SLE damage independent of inflammation in Ghanaian SLE patients. , 2018, , .		0
65	AI-06...Lupus nephritis is linked to dysbiosis, increased gut leakiness and immunity to an intestinal commensal lachnospiraceae species. , 2018, , .		0
66	Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1742-1749.	0.5	40
67	Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis. <i>Lupus Science and Medicine</i> , 2018, 5, e000271.	1.1	8
68	Brief Report: Tubulointerstitial Damage in Lupus Nephritis: A Comparison of the Factors Associated With Tubulointerstitial Inflammation and Renal Scarring. <i>Arthritis and Rheumatology</i> , 2018, 70, 1801-1806.	2.9	34
69	Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 36.	1.6	20
70	The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. <i>Rheumatology</i> , 2018, 57, v9-v17.	0.9	47
71	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , 2018, 5, e000263.	1.1	18
72	Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus. <i>Journal of Autoimmunity</i> , 2017, 79, 99-104.	3.0	13

#	ARTICLE	IF	CITATIONS
73	Activated Platelets Induce Endothelial Cell Activation via an Interleukin-1 $\beta$ Pathway in Systemic Lupus Erythematosus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 707-716.	1.1	77
74	Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. <i>Current Opinion in Rheumatology</i> , 2017, 29, 467-472.	2.0	39
75	Cardiac fibroblast transcriptome analyses support a role for interferogenic, profibrotic, and inflammatory genes in anti-SSA/Ro-associated congenital heart block. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 313, H631-H640.	1.5	15
76	Brief Report: Association of Natural Killer Cell Ligand Polymorphism HLA-C Asn80Lys With the Development of Anti-SSA/Ro-Associated Congenital Heart Block. <i>Arthritis and Rheumatology</i> , 2017, 69, 2170-2174.	2.9	11
77	The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program. <i>Arthritis and Rheumatology</i> , 2017, 69, 2006-2017.	2.9	126
78	Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. <i>Autoimmunity Reviews</i> , 2017, 16, 980-983.	2.5	25
79	Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis. <i>JCI Insight</i> , 2017, 2, .	2.3	164
80	Apolipoprotein L1 risk variants associate with prevalent atherosclerotic disease in African American systemic lupus erythematosus patients. <i>PLoS ONE</i> , 2017, 12, e0182483.	1.1	21
81	No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 857-859.	0.4	4
82	Neonatal Lupus. , 2016, , 451-461.		1
83	Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. <i>Arthritis and Rheumatology</i> , 2016, 68, 1964-1969.	2.9	33
84	Endosomal Toll-like receptors in clinically overt and silent autoimmunity. <i>Immunological Reviews</i> , 2016, 269, 76-84.	2.8	35
85	Modulation of natural IgM autoantibodies to oxidative stress-related neo-epitopes on apoptotic cells in newborns of mothers with anti-Ro autoimmunity. <i>Journal of Autoimmunity</i> , 2016, 73, 30-41.	3.0	10
86	Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2016, 3, e000165.	1.1	18
87	Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. <i>Cell</i> , 2016, 166, 88-101.	13.5	340
88	Neonatal Lupus Erythematosus. , 2016, , 336-350.e8.		2
89	Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. <i>Lupus Science and Medicine</i> , 2016, 3, e000131.	1.1	118
90	Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1161-1165.	0.5	81

#	ARTICLE	IF	CITATIONS
91	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016, 12, 137-156.	1.3	118
92	Targeting downstream transcription factors and epigenetic modifications following Toll-like receptor 7/8 ligation to forestall tissue injury in anti-Ro60 associated heart block. Journal of Autoimmunity, 2016, 67, 36-45.	3.0	19
93	Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. American Journal of Obstetrics and Gynecology, 2016, 214, 108.e1-108.e14.	0.7	122
94	Blockade of Interferon- $\beta$ Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2015, 67, 2713-2722.	2.9	60
95	A highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Science and Medicine, 2015, 2, e000087.	1.1	12
96	Predictors of Pregnancy Outcomes in Patients With Lupus. Annals of Internal Medicine, 2015, 163, 153-163.	2.0	393
97	The clinical spectrum of autoimmune congenital heart block. Nature Reviews Rheumatology, 2015, 11, 301-312.	3.5	209
98	Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. Journal of Rheumatology, 2015, 42, 2288-2295.	1.0	79
99	Reactivity to the p305 Epitope of the $\beta$ -Type Calcium Channel and Autoimmune-Associated Congenital Heart Block. Journal of the American Heart Association, 2015, 4, .	1.6	7
100	Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus. Journal of the American College of Cardiology, 2015, 66, 930-939.	1.2	32
101	Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issue. Lupus Science and Medicine, 2014, 1, e000033.	1.1	0
102	Prevention and Treatment In Utero of Autoimmune-Associated Congenital Heart Block. Cardiology in Review, 2014, 22, 263-267.	0.6	90
103	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Science and Medicine, 2014, 1, e000056.	1.1	65
104	Neonatal Lupus. , 2014, , 251-272.		3
105	A 2014 update on the management of patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 2014, 44, e1-e2.	1.6	17
106	Relation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosus. Clinical Immunology, 2014, 153, 1-7.	1.4	36
107	Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials." by Gleicher N, Elkayam U, Autoimmun Rev. 2013 Sep;12(11):1039-45. Autoimmunity Reviews. 2014. 13. 70-72.	2.5	7
108	Active systemic lupus erythematosus is associated with decreased blood conventional dendritic cells. Experimental and Molecular Pathology, 2013, 95, 121-123.	0.9	9

#	ARTICLE	IF	CITATIONS
109	Ro60 Requires Y3 RNA for Cell Surface Exposure and Inflammation Associated with Cardiac Manifestations of Neonatal Lupus. <i>Journal of Immunology</i> , 2013, 191, 110-116.	0.4	47
110	A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies. <i>Rheumatology</i> , 2013, 52, 1448-1453.	0.9	11
111	Complement Receptor 3 Influences Toll-like Receptor 7/8-Dependent Inflammation. <i>Journal of Biological Chemistry</i> , 2013, 288, 9077-9083.	1.6	48
112	Anatomical and pathological findings in hearts from fetuses and infants with cardiac manifestations of neonatal lupus. <i>Rheumatology</i> , 2012, 51, 1086-1092.	0.9	96
113	Neonatal lupus. <i>Current Opinion in Rheumatology</i> , 2012, 24, 466-472.	2.0	44
114	Cardiac Manifestations of Neonatal Lupus. <i>Cardiology in Review</i> , 2012, 20, 72-76.	0.6	61
115	Dysregulation of the Microvasculature in Nonlesional Non-Sun-exposed Skin of Patients with Lupus Nephritis. <i>Journal of Rheumatology</i> , 2012, 39, 510-515.	1.0	6
116	Maternal Use of Hydroxychloroquine Is Associated With a Reduced Risk of Recurrent Anti-SSA/Ro-Antibody-Associated Cardiac Manifestations of Neonatal Lupus. <i>Circulation</i> , 2012, 126, 76-82.	1.6	363
117	Umbilical cord blood levels of maternal antibodies reactive with p200 and full-length Ro 52 in the assessment of risk for cardiac manifestations of neonatal lupus. <i>Arthritis Care and Research</i> , 2012, 64, 1373-1381.	1.5	39
118	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
119	Neonatal Lupus. , 2011, , 541-571.		11
120	Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. <i>Arthritis and Rheumatism</i> , 2011, 63, 2783-2789.	6.7	30
121	Maternal and Fetal Factors Associated With Mortality and Morbidity in a Multi-Racial/Ethnic Registry of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus. <i>Circulation</i> , 2011, 124, 1927-1935.	1.6	257
122	A Novel Role of Endothelin-1 in Linking Toll-like Receptor 7-mediated Inflammation to Fibrosis in Congenital Heart Block. <i>Journal of Biological Chemistry</i> , 2011, 286, 30444-30454.	1.6	55
123	Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 1138-1146.	6.7	211
124	Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. <i>Arthritis and Rheumatism</i> , 2010, 62, 1153-1157.	6.7	119
125	Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. <i>Arthritis and Rheumatism</i> , 2010, 62, 3415-3424.	6.7	84
126	Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1827-1830.	0.5	192

#	ARTICLE	IF	CITATIONS
127	Ro60-Associated Single-Stranded RNA Links Inflammation with Fetal Cardiac Fibrosis via Ligation of TLRs: A Novel Pathway to Autoimmune-Associated Heart Block. <i>Journal of Immunology</i> , 2010, 184, 2148-2155.	0.4	89
128	Congenital heart block: Identification of autoantibody binding site on the extracellular loop (domain) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	3.0	59
129	Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 89-95.	1.0	51
130	Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. <i>Nature Reviews Rheumatology</i> , 2009, 5, 139-148.	3.5	73
131	Prospective Evaluation of Fetuses With Autoimmune-Associated Congenital Heart Block Followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. <i>American Journal of Cardiology</i> , 2009, 103, 1102-1106.	0.7	171
132	Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. <i>Arthritis and Rheumatism</i> , 2009, 60, 3091-3097.	6.7	135
133	Updates on lupus and pregnancy. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2009, 67, 271-5.	0.7	14
134	Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart Block. <i>Circulation</i> , 2008, 117, 485-493.	1.6	282
135	Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. <i>Rheumatology</i> , 2008, 48, 513-519.	0.9	24
136	Neonatal Lupus Syndromes. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 267-285.	0.8	84
137	Estrogens and lupus: Bubbling cauldron or another overrated Witches' Brew?. <i>Arthritis and Rheumatism</i> , 2007, 56, 1048-1050.	6.7	6
138	Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. <i>Current Rheumatology Reports</i> , 2007, 9, 101-108.	2.1	80
139	The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2006, 54, 3623-3632.	6.7	130
140	Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. <i>Journal of Clinical Investigation</i> , 2006, 116, 2413-22.	3.9	140
141	The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2005, 142, 953.	2.0	539
142	Autoantibody-associated congenital heart block: TGF $\beta$ 2 and the road to scar. <i>Autoimmunity Reviews</i> , 2005, 4, 1-7.	2.5	37
143	Identifying an early marker for congenital heart block: When is a long PR interval too long? Comment on the article by Sonesson et al. <i>Arthritis and Rheumatism</i> , 2005, 52, 1341-1342.	6.7	10
144	Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. <i>Arthritis and Rheumatism</i> , 2005, 52, 3079-3086.	6.7	64

#	ARTICLE	IF	CITATIONS
145	Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2005, 353, 2550-2558.	13.9	962
146	Neonatal Lupus: Basic Research and Clinical Perspectives. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 299-313.	0.8	84
147	Autoantibodies against the serotonergic 5-HT <sub>4</sub> receptor and congenital heart block: A reassessment. <i>Journal of Autoimmunity</i> , 2005, 25, 72-76.	3.0	32
148	The Fetal Doppler Mechanical PR Interval: A Validation Study. <i>Fetal Diagnosis and Therapy</i> , 2004, 19, 31-34.	0.6	71
149	Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. <i>Arthritis and Rheumatism</i> , 2004, 50, 173-182.	6.7	135
150	Genetic association of cutaneous neonatal lupus with HLA class II and tumor necrosis factor $\gamma$ : Implications for pathogenesis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2598-2603.	6.7	46
151	Anti-52 kDa Ro, anti-60 kDa Ro, and anti-La antibody profiles in neonatal lupus. <i>Journal of Rheumatology</i> , 2004, 31, 2480-7.	1.0	90
152	Autoantibody-associated congenital heart block: The clinical perspective. <i>Current Rheumatology Reports</i> , 2003, 5, 374-378.	2.1	5
153	Maternal autoantibodies and congenital heart block: mediators, markers, and therapeutic approach. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 33, 140-154.	1.6	70
154	From antibody insult to fibrosis in neonatal lupus - the heart of the matter. <i>Arthritis Research</i> , 2003, 5, 266.	2.0	16
155	Letter to the Editor. <i>Lupus</i> , 2003, 12, 646-647.	0.8	64
156	Cytokine Polymorphisms and Histologic Expression in Autopsy Studies: Contribution of TNF- $\alpha$ and TGF- $\beta$ 1 to the Pathogenesis of Autoimmune-Associated Congenital Heart Block. <i>Journal of Immunology</i> , 2003, 171, 3253-3261.	0.4	92
157	Neonatal Lupus: Review of Proposed Pathogenesis and Clinical Data from the US-based Research Registry for Neonatal Lupus. <i>Autoimmunity</i> , 2003, 36, 41-50.	1.2	74
158	Clearance of apoptotic cells: TGF- $\beta$ 2 in the balance between inflammation and fibrosis. <i>Journal of Leukocyte Biology</i> , 2003, 74, 959-960.	1.5	35
159	Neonatal lupus syndromes. <i>Current Opinion in Rheumatology</i> , 2003, 15, 535-541.	2.0	76
160	Neonatal Lupus Syndromes: Clinical Features. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, , 163-188.	0.1	1
161	Transdifferentiation of Cardiac Fibroblasts, a Fetal Factor in Anti-SSA/Ro-SSB/La Antibody-Mediated Congenital Heart Block. <i>Journal of Immunology</i> , 2002, 169, 2156-2163.	0.4	94
162	Hepatobiliary Disease in Neonatal Lupus: Prevalence and Clinical Characteristics in Cases Enrolled in a National Registry. <i>Pediatrics</i> , 2002, 109, e11-e11.	1.0	132

#	ARTICLE	IF	CITATIONS
163	Cardiac 5-HT <sub>4</sub> Serotonergic Receptors, 52kD SSA/Ro and Autoimmune-Associated Congenital Heart Block. <i>Journal of Autoimmunity</i> , 2002, 19, 79-86.	3.0	29
164	Subcellular redistribution of La/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system. <i>Arthritis and Rheumatism</i> , 2002, 46, 202-208.	6.7	69
165	The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: Implications in neonatal lupus. <i>Arthritis and Rheumatism</i> , 2002, 46, 269-271.	6.7	26
166	Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. <i>Arthritis and Rheumatism</i> , 2002, 46, 1572-1579.	6.7	83
167	Long-term followup of children with neonatal lupus and their unaffected siblings. <i>Arthritis and Rheumatism</i> , 2002, 46, 2377-2383.	6.7	149
168	Congenital heart block in neonatal lupus: The pediatric cardiologist's perspective. <i>Indian Journal of Pediatrics</i> , 2002, 69, 517-522.	0.3	33
169	Subcellular redistribution of La/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system. , 2002, 46, 202.		2
170	Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. <i>Journal of the American College of Cardiology</i> , 2001, 37, 238-242.	1.2	360
171	Circulating activated endothelial cells in systemic lupus erythematosus: Further evidence for diffuse vasculopathy. <i>Arthritis and Rheumatism</i> , 2001, 44, 1203-1208.	6.7	111
172	High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin. <i>Arthritis and Rheumatism</i> , 2001, 44, 1466-1467.	6.7	187
173	Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2000, 43, 550.	6.7	162
174	Pulsed Doppler echocardiographic assessment of the fetal PR interval. <i>American Journal of Cardiology</i> , 2000, 86, 236-239.	0.7	148
175	Clinical trials in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2000, 2, 11-12.	2.1	2
176	Anti-SSA/Ro and Anti-SSB/La Autoantibodies Bind the Surface of Apoptotic Fetal Cardiocytes and Promote Secretion of TNF- $\alpha$ by Macrophages. <i>Journal of Immunology</i> , 2000, 165, 5345-5351.	0.4	181
177	Cutaneous manifestations of neonatal lupus without heart block: Characteristics of mothers and children enrolled in a national registry. <i>Journal of Pediatrics</i> , 2000, 137, 674-680.	0.9	231
178	Electrocardiographic Abnormalities in a Murine Model Injected With IgG From Mothers of Children With Congenital Heart Block. <i>Circulation</i> , 1999, 99, 1914-1918.	1.6	84
179	Assessing disease activity in SLE patients during pregnancy. <i>Lupus</i> , 1999, 8, 677-684.	0.8	166
180	Classification and definition of major flares in SLE clinical trials. <i>Lupus</i> , 1999, 8, 685-691.	0.8	220

#	ARTICLE	IF	CITATIONS
181	Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: Retrospective review of the research registry for neonatal lupus. <i>Arthritis and Rheumatism</i> , 1999, 42, 2335-2345.	6.7	291
182	mRNA and Protein Expression of SSA/Ro and SSB/La in Human Fetal Cardiac Myocytes Cultured Using a Novel Application of the Langendorff Procedure. <i>Pediatric Research</i> , 1999, 45, 260-269.	1.1	18
183	Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. <i>Arthritis and Rheumatism</i> , 1998, 41, 1026-1039.	6.7	86
184	Autoimmune-Associated Congenital Heart Block: Demographics, Mortality, Morbidity and Recurrence Rates Obtained From a National Neonatal Lupus Registry. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1658-1666.	1.2	700
185	The effects of pregnancy on autoimmune diseases. <i>Journal of Leukocyte Biology</i> , 1998, 63, 281-287.	1.5	120
186	Serum and Immunoglobulin G from the Mother of a Child with Congenital Heart Block Induce Conduction Abnormalities and Inhibit L-Type Calcium Channels in a Rat Heart Model. <i>Pediatric Research</i> , 1998, 44, 11-19.	1.1	88
187	Differential phosphorylation of the $\beta$ 2 integrin CD11b/CD18 in the plasma and specific granule membranes of neutrophils. <i>Journal of Leukocyte Biology</i> , 1997, 61, 313-321.	1.5	20
188	NEONATAL LUPUS SYNDROMES. <i>Rheumatic Disease Clinics of North America</i> , 1997, 23, 31-54.	0.8	85
189	The 52-kd protein as a target of intermolecular spreading of the immune response to components of the SS-A/Ro-SS-B/La complex. <i>Arthritis and Rheumatism</i> , 1997, 40, 936-944.	6.7	69
190	Connective tissue disease registries. <i>Arthritis and Rheumatism</i> , 1997, 40, 1556-1559.	6.7	20
191	Arrhythmogenicity of IgG and Anti-52-kD SSA/Ro Affinity-Purified Antibodies From Mothers of Children With Congenital Heart Block. <i>Circulation Research</i> , 1997, 80, 354-362.	2.0	144
192	The Effects of Pregnancy on Autoimmune Diseases. <i>Clinical Immunology and Immunopathology</i> , 1996, 78, 99-104.	2.1	37
193	Cloning and expression of mouse 60 kDa ribonucleoprotein SS-A/Ro. <i>Molecular Biology Reports</i> , 1996, 23, 205-210.	1.0	31
194	Heterogeneity in the expression of ro and la antigens in human skin. <i>Arthritis and Rheumatism</i> , 1995, 38, 1271-1276.	6.7	17
195	Successful in utero therapy of fetal heart block. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 173, 1384-1390.	0.7	133
196	Up-Regulation of Endothelial Cell Adhesion Molecules Characterizes Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 1994, 37, 376-383.	6.7	171
197	Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-ss-a/ro and anti-ss-b/la antibodies. <i>Arthritis and Rheumatism</i> , 1993, 36, 1263-1273.	6.7	208
198	Review: Congenital Complete Heart Block. <i>Lupus</i> , 1993, 2, 291-295.	0.8	28

#	ARTICLE	IF	CITATIONS
199	Activation of the Complement Pathway: Comparison of Normal Pregnancy, Preeclampsia, and Systemic Lupus Erythematosus During Pregnancy. <i>American Journal of Reproductive Immunology</i> , 1992, 28, 183-187.	1.2	53
200	Activation of the Alternative Complement Pathway Accompanies Disease Flares in Systemic Lupus Erythematosus During Pregnancy. <i>Arthritis and Rheumatism</i> , 1992, 35, 55-61.	6.7	90
201	Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. <i>Arthritis and Rheumatism</i> , 1992, 35, 1028-1037.	6.7	104
202	Onset and Regulation of Anti-Lamin b Autoantibody Production is Independent of the Level of Polyclonal Activation. <i>Autoimmunity</i> , 1991, 8, 297-305.	1.2	11
203	Serum activity that confers acid lability to $\hat{I}\pm$ -interferon in systemic lupus erythematosus: its association with disease activity and its independence from circulating $\hat{I}\pm$ -interferon. <i>Arthritis and Rheumatism</i> , 1990, 33, 563-568.	6.7	20
204	Congenital complete heart block. <i>Arthritis and Rheumatism</i> , 1990, 33, 609-614.	6.7	108
205	Effective separation of the 52 kDa SSA/Ro polypeptide from the 48 kDa SSB/La polypeptide by altering conditions of polyacrylamide gel electrophoresis. <i>Journal of Immunological Methods</i> , 1990, 129, 207-210.	0.6	82
206	Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. <i>Arthritis and Rheumatism</i> , 1988, 31, 632-641.	6.7	115
207	Intrauterine therapy for presumptive fetal myocarditis with acquired heart block due to systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1987, 30, 44-49.	6.7	154
208	Female hormones reduce neutrophil responsiveness in vitro. <i>Arthritis and Rheumatism</i> , 1984, 27, 623-630.	6.7	108
209	Evaluation of the European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population Based Registry. <i>Arthritis Care and Research</i> , 0, , .	1.5	2
210	To Be or Not to Be Treated: That Is the Question in Managing a Fetus With Cardiac Injury Exposed to Anti-SSA/Ro. <i>Journal of the American Heart Association</i> , 0, , .	1.6	1